The Academic Clinical Division capitalizes on LLS's academic grant-supported portfolio of clinical development-stage projects. This division supports the clinical development of selected academic projects (with or without prior LLS grant support) to gain clinical proof of concept. Successful projects will potentially be advanced for further clinical development by creating additional partnerships with pharmaceutical or biotechnology companies.
TAP funding is different from the traditional grant at LLS. The TAP review process is separate from the grant process and each approved project is closely monitored by TAP staff.
For information on how to apply to TAP, please click here.
Clinical Studies Ongoing
Oregon Health & Science University and The Leukemia & Lymphoma Society
CSF1R Inhibitor JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia
This phase II trial studies how well FMS inhibitor JNJ-40346527 works in treating participants with acute myeloid leukemia that has come back or does not respond to treatment. FMS inhibitor JNJ-40346527 may stop the growth of cancer cells by blocking some of the microenvironmental signals needed for cell growth.
Participants receive FMS inhibitor JNJ-40346527 orally (PO) twice a day (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, participants are followed up within 2 weeks, at 4-6 weeks until death or minimum of 12 months.
ClinicalTrials.gov identifier: NCT03557970
For more information contact :
Elie Traer, MD
OHSU Knight Cancer Institute
Portland, Oregon, United States, 97239
Visit the Oregon Health & Science University Knight Cancer Institute website for additional information.
Case Western Reserve and The Leukemia & Lymphoma Society
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
This is a phase I study with "3+3" design with three planned dose levels of NK cells and a fixed dose of ALT-803. Three patients will be enrolled sequentially to each dose level, starting with dose level 1. Patients will be segregated to either receive ALT803 as cytokine support after NK cell infusion (starting with same dose level as Level 1) or no cytokine administration. Patients in the arm receiving ALT803 will be either hematologic malignancy patients (Cohort A) or Colon/Soft tissue sarcoma patients (Cohort B). Absence of dose limiting toxicity (DLT) in the DLT assessment period of 28 days must be documented for all patients enrolled a cell dose without ALT803 before the next cohort of patients to receive cytokines at that dose level can be enrolled. Patients can also be enrolled in parallel to the next cell dose level without cytokines.
ClinicalTrials.gov identifier: NCT02890758
For more information contact:
David Wald, MD, PhD
University Hospitals Cleveland Medical Center
Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States, 44106
Visit the Case Western Reserve website for additional information.
Massachusetts General Hospital and The Leukemia & Lymphoma Society
A Phase I Clinical Trial With CAR-37 T Cells for the Treatment of Patients With Relapsed or Refractory CD37+ Hematologic Malignancies
This is a two-part, non randomized, open label, single site Phase 1 study. Participants who fulfill eligibility criteria will be entered into the trial Chimeric Antigen Receptor (CAR)-37 T Cells (CAR-37 T Cells).
Part A (Dose Escalation): The investigators are looking the highest dose of the study intervention that can be administered safely without severe or unmanageable side effects in participants that have relapsed or refractory CD37+ hematologic malignancies, not everyone who participates in this research study will receive the same dose of the study intervention. The dose given will depend on the number of participants who have been enrolled prior and how well the dose was tolerated
Part B (Expansion Cohort): Part B: Expansion Cohort: Participants will be treated at the respective dose (at or below the Maximum Tolerated Dose), as determined during Part A (Dose Escalation).
A total of 18 participants will be enrolled to this trial.
This is the first time that CAR-37 T Cells will be given to humans.
ClinicalTrials.gov identifier: NCT04136275
For more information contact:
Matthew J. Frigault, MD
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States, 02114
Visit the Massachusetts General Hospital website for additional information.
If you'd like your organization to be considered for TAP funding, you must meet the following criteria:
Your organization must have active proprietary projects in the blood cancer field.
Your project must be at a late preclinical or an early clinical development stage.
The compounds, biologics or diagnostics in development must have a high, near-term probability of providing benefits to patients.
The funding TAP provides is not a grant.
LLS's TAP team reviews all organizations that make an inquiry but will only invite those deemed to meet diligence criteria to complete a proposal template and be considered for TAP funding.
To submit an inquiry for initial non-confidential review, please click here to download the form.
Send a completed inquiry form and non-confidential presentation to Dr. Blaine Robinson, Executive Director, Therapy Acceleration Program®, The Leukemia & Lymphoma Society, 3 International Drive, Suite 200, Rye Brook, NY 10573; firstname.lastname@example.org.